AQR Capital Management
CRSP icon

AQR Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

AQR Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.06M Buy
22,268
+1,522
+7% +$80.3K ﹤0.01% 2732
2025
Q4 		$1.09M Sell
20,746
-7,626
-27% -$457K ﹤0.01% 2495
2025
Q3 		$1.84M Buy
28,372
+6,758
+31% +$388K ﹤0.01% 2022
2025
Q2 		$1.05M Sell
21,614
-3,692
-15% -$143K ﹤0.01% 2179
2025
Q1 		$861K Buy
+25,306
New +$1.07M ﹤0.01% 2124
2022
Q3 		– Sell
-8,505
Closed -$517K – 2222
2022
Q2 		$517K Sell
8,505
-578
-6% -$34K ﹤0.01% 1672
2022
Q1 		$570K Buy
9,083
+2,310
+34% +$145K ﹤0.01% 1770
2021
Q4 		$513K Buy
6,773
+2,911
+75% +$254K ﹤0.01% 1817
2021
Q3 		$432K Buy
3,862
+1,661
+75% +$209K ﹤0.01% 1917
2021
Q2 		$356K Buy
+2,201
New +$268K ﹤0.01% 1998

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management's CRSP Position: Q1 2026 in Review

AQR Capital Management increased its CRISPR Therapeutics (CRSP) stake by 7.3% in Q1 2026, buying an estimated $80.3K and bringing the position to 22,268 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

AQR Capital Management first reported a position in CRSP in Q2 2021 and has held it in 10 quarters since. The position peaked at $1.84M in Q3 2025. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • AQR Capital Management held 22,268 shares of CRISPR Therapeutics worth $1.06M as of Q1 2026.
  • AQR Capital Management bought 1,522 CRISPR Therapeutics shares in Q1 2026, an estimated $80.3K.
  • CRISPR Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #2732 holding.
  • AQR Capital Management first reported a position in CRISPR Therapeutics in Q2 2021 and has held it in 10 quarters since.
  • AQR Capital Management's CRISPR Therapeutics position peaked at $1.84M in Q3 2025.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.